Today (3/7/2020) is the day of the CME Webinar “Diagnosing Nasopharyngeal Cancer and State of the Art Radiotherapy Treatment” with our Consultants:Consultant Clinical Oncologist, Dr Ng Boon Huat.Consultant ENT Surgeon, Dr Raymond Tan Suan-Kuo.
Author: Dr Ng Boon Huat, Clinical Oncologist, Malaysia
Problem As the visiting oncologist to IIUMMC, I'm unable to attend my weekly oncology clinic at IIUMMC @ Kuantan, Pahang due to movement control order (MCO). Cancer patients need treatment fast (surgery, chemotherapy, radiotherapy) in order to achieve higher cure rate for early stage cancer and to improve control of advanced stage cancer. Innovate, not … Continue reading Cancer: 1st Free Video Consultation for Cancer Patients
Video Consultation, Reaching Out To Cancer Patients Everywhere Due to Malaysia's Movement Control Order (MCO), a lot of cancer patients, especially those who are newly diagnosed, will not be able to proceed with immediate surgery, chemotherapy and radiotherapy. Most patients may not even know what to do next because they are unable to visit an … Continue reading Malaysia Movement Control Order (MCO): Free First Video Consultation for All Cancer Patients.
Not all lung cancers are of the same type, stage or treated similarly. In a nutshell... A. Targeted therapy For stage 4 lung adenocarcinoma (subset of NSCLC), further testing of EFGR and EML4-ALK mutation are routinely done in Malaysia. ROS1 rearranged mutation driver testing is not routinely done although targetable treatment is available. Those with … Continue reading Stage 4 Lung Cancer: Targeted therapy & Immunotherapy. Which to Start?
The first paragraph summed it well - drastic price reduction would enable more breast cancer patients with HER2-positive to be treated with trastuzumab. Trastuzumab treatment is heavily subsidised for patients who fits certain strict criterias in government hospitals. For these patients, this news won't affect them. Who will it benefit then? Besides adhering to KKM … Continue reading Good News for Breast Cancer Patients (with HER2-positive)